OnKure Therapeutics, Inc. Class A Common Stock (OKUR)

PHARMACEUTICAL PREPARATIONS

Headquarters
United States
Employees
45
Market Cap
$159M

About OnKure Therapeutics, Inc. Class A Common Stock

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.

SentiSense also tracks daily options readings for OnKure Therapeutics, Inc. Class A Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

OnKure Therapeutics, Inc. Class A Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.